Although exendin-4 still lacked the extended half-life required to be effective for glycemic control, it set the foundation for the development of new GLP-1 analogs relatively resistant to dipeptidyl peptidase-4 with prolonged half-lives revolutionizing the treatment of obesity and type 2 diabetes. This evidence concerns the gene GCG and obesity disorder.